{"id":1295,"date":"2019-07-02T14:51:29","date_gmt":"2019-07-02T12:51:29","guid":{"rendered":"https:\/\/www.euromedlab2021munich.org\/?page_id=1295"},"modified":"2022-03-29T13:59:09","modified_gmt":"2022-03-29T11:59:09","slug":"scientic_program","status":"publish","type":"page","link":"https:\/\/www.euromedlab2021munich.org\/index.php\/scientic_program\/","title":{"rendered":"Scientific Programme"},"content":{"rendered":"

[vc_row][vc_column][vc_accordion active_tab=”1″ collapsible=”yes” style=”2″][vc_accordion_tab title=”DAY 1″]

<\/div>

Sunday 10 April<\/h2><\/div>
OPENING CEREMONY <\/strong> | Room 14<\/span><\/div><\/div>
    \n
  • 17.00\u00a0Welcome Addresses
    \nSpeakers: K. Lackner (Germany), M. Neumaier (Germany), K. Adeli (Canada), T. Ozben (Turkey), H. Renz (Germany)<\/li>\n
  • 17.30\u00a0Announcement of EFLM Awards
    \nChair:\u00a0T.\u00a0Ozben\u00a0(Turkey)<\/li>\n
  • 18.00\u00a0Opening Lecture
    \nWhere, when, and how? The Quest for Extraterrestrial Life
    \nChair:\u00a0M. Neumaier\u00a0(Germany)
    \nSpeaker: W. Duschl (Germany)<\/li>\n
  • 19.00 Welcome Cocktail<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 2″]
    <\/div>

    Monday, 11 April<\/h2><\/div><\/div>
      \n
    • 9:00-10:00 PLENARY LECTURE<\/strong> | Room 1<\/span>
      \nChair: P. Gillery (France)
      \nFine tuning of innate immunity – T. Chavakis (Germany)<\/em><\/li>\n
    • 10:00-10:30 Break<\/li>\n
    • 10:30-12:30 SYMPOSIUM 1<\/strong> | Room 1<\/span>
      \nAcute Kidney Injury biomarkers: from lab to bedside<\/strong> – Chairs: C. Ronco (Italy), F. Alcantara (Brazil)<\/em>
      \nThe continuum of AKI and the utility of biomarkers – C. Ronco (Italy)<\/em>
      \nNew Biomarkers in AKI: application in clinical routine – L- Forni (UK)<\/em>
      \nPrevention\/protection of the kidney guided by biomarkers – M. Ostermann (UK)
      \n<\/em><\/em>Urinary kidney injury biomarkers determined by LC-MRM-MS in health and disease – T. van Duijl (The Netherlands)<\/em>
      \nThe role of the laboratory in the early detection of acute kidney injury in hospitalised patients – Rachel Galv\u00e1n <\/em>(Spain)<\/em><\/li>\n
    • 10:30-12:30 SYMPOSIUM 2<\/strong>| Room 5<\/span>
      \nChronic myeloproliferative neoplasms<\/strong> – Chairs: D. Coriu (Romania), S.N. Constantinescu (Belgium)<\/em>
      \nDiagnostic algorithm in myeloproliferative neoplasms – D. Coriu (Romania)<\/em>
      \nInhibiting pathologic signaling induced by driver and epigenetic mutations in myeloproliferative neoplasms: monitoring treatment by next generation sequencing – S.N. Constantinescu (Belgium)<\/em>
      \nChallenges of using next-generation sequencing technologies in the clinical management of myeloproliferative neoplasms – C. Mambet (Romania)
      \n<\/em><\/em>ALNeT: a new deep learning model for the diagnosis of acute leukaemia lineage using peripheral blood cell images – J. Rodellar (Spain)<\/em><\/li>\n
    • 10:30-12:30 SYMPOSIUM 3<\/strong> | Room 13a<\/span>
      \nPerformance Specifications in Laboratory Medicine \u2013 from different models to practical use<\/strong> – Chairs: S. Sandberg (Norway), A. R. Horvath (Australia)<\/em>
      \nAnalytical performance specifications: From models to practical use – S. Sandberg (Norway)<\/em>
      \nOutcome-based models \u2013 a link between clinical and analytical performance – A.R. Horvath (Australia)<\/em>
      \nA practical way of calculating measurement uncertainty in laboratory medicine and compare it to APS – A. Coskun (Turkey)
      \n<\/em><\/em>Analytical Performance Specifications Derived from Uncertainty Budgets Based on Clinical Decision Limits – E.S. Rotgers (Finland)<\/em><\/li>\n
    • 10:30-12:30 SYMPOSIUM 4<\/strong> | Room 13b<\/span>
      \nClinical Use Cases for Integrated diagnostics for Laboratory Medicine and Radiology<\/strong> – Chairs: M. Fuchsj\u00e4ger (Austria), M. Neumaier (Germany)<\/em>
      \nEIBIR, a support platform for research funding in future integrative diagnostics between imaging and the laboratory \u2013 K. Krischak (Austria)<\/em>
      \nPersonalized Diagnostics in detection of recurrence of metastatic colorectal cancer \u2013 S. Sch\u00f6nberg (Germany), V. Haselmann (Germany) <\/em>
      \nPrediction of prognosis based on laboratory data and chest CT \u2013 S. Cappabianca (Italy)<\/em>
      \nIntegrative diagnostics to investigate tissue damage dynamics \u2013 M. Fr\u00f6lich (Germany), C. Gerhards (Germany)<\/em><\/li>\n
    • 10:30-12:30 SYMPOSIUM 5<\/strong> | Room 14a<\/span>
      \nCOVID-19: biology, clinics, laboratory diagnostics and biosafety issues<\/strong> – Chairs: G. Lippi (Italy),K. Adeli (Canada)<\/em>
      \nBiology and clinics of COVID-19 – G. Lippi (Italy)<\/em>
      \nMolecular and serological testing of COVID-19 – K. Adeli (Canada)<\/em>
      \nLaboratory responsiveness to COVID-19: results of an IFCC survey – T.P. Loh<\/em>\u00a0(Singapore)<\/em>
      \nClinical laboratory testing in a pandemic: what we have learned from the COVID-19 experience – D. Koch (USA)<\/em><\/li>\n
    • 10:30-12:30 DGKL SYMPOSIUM<\/strong> | Room 14c<\/span>
      \nMetabolomics via NMR spectroscopy<\/strong> – Chairs: M. Nauck (Germany), U. G\u00fcnther (Germany)<\/em>
      \nLipoprotein diagnostics via NMR. From research to clinical application – M. Nauck (Germany)<\/em>
      \nBlood Lipo- and Glycoproteins in COVID-19 Patients –\u00a0U. Gunther (Germany)<\/em>
      \nNMR Biomarker Research: Targeted and untargeted approach – A. Petersmann (Germany)<\/em>
      \nAssociation of triacylgcerol-glucose index with low-density lipoprotein particle number and size measured by proton nuclear magnetic resonance spectroscopy – O. Racz (Slovakia)<\/em>
      \nSerum Metabolome Analysis of Iron Deficiency Anemia Patients Using Nuclear Magnetic Resonance (Quantitative Approach) –\u00a0A.Z. Gul (Turkey)<\/em><\/li>\n
    • 12:30-14:00 POSTER SESSION<\/strong>| Hall C1<\/span><\/li>\n
    • 14:00-16:00 SYMPOSIUM 6<\/strong> | Room 14c<\/span>
      \nArtificial intelligence, data science and laboratory medicine: crossed destinies<\/strong> – Chairs: D. Gruson (Belgium), M. Cowie (UK)<\/em>
      \nThe AI data wave, seizing opportunities – M. Cowie (UK)<\/em>
      \nHow to dive into large scale dataset? – B. Macq (Belgium)<\/em>
      \nWhat are the keys for Europe as a space for data and AI? – Y. Tolias (Belgium)
      \n<\/em>Round Table – M. Cowie, B. Macq, Y. Tolias<\/em><\/li>\n
    • 15:30-16:30 VIEWPOINT 1<\/strong> | Room 1<\/span>
      \nIs eGFR the gold standard for evaluating renal dysfunction?<\/strong> – Chair: K. Makris (Greece)<\/em>
      \nMeasuring GFR\u2013tohubohu – E. Schaeffner (Germany)<\/em>
      \nEstimating eGFR: no blind trust – C. Mariat (France)<\/em><\/li>\n
    • 17:00-18:00 VIEWPOINT 2<\/strong> | Room 1<\/span>
      \nQuantitative mass spectrometry vs immunoassays of clinically relevant peptides and proteins.<\/strong> – Chair: C. Cobbaert (Netherlands)<\/em>
      \nCan quantitative mass spectrometry replace immunoassays for blood proteins? The only question is when? – C. Borchers (Canada)<\/em>
      \nQuantitative mass spectrometry cannot replace immunossays for blood proteins – S. Lehmann (France)<\/em><\/li>\n
    • 17:00-18:00\u00a0SESSION<\/strong>\u00a0|\u00a0Room 14c<\/span>
      \nContainment of a viral pandemic: is diagnostic performance rate-limiting?<\/strong>\u00a0\u2013\u00a0Chairs: M. Kittel (Germany), M. Neumaier (Germany)<\/em>
      \nLessons from the CoVLAB initiative: diagnostic performance vs scalability \u2013\u00a0M. Kittel (Germany)<\/em>
      \nPebble: filling-in the gap of point-of-care molecular testing \u2013 S. Katsaros (Greece), D. Kourougkiaouri (Greece)<\/em>
      \nRational clinical use of POCT methods for molecular detection of infectious agents \u2013\u00a0P. Luppa (Germany)<\/em><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 3″]
      <\/div>

      Tuesday, 12 April<\/h2><\/div><\/div>
        \n
      • 9:00-10:00 PLENARY LECTURE<\/strong> | Room 1<\/span>
        \nChair: K. Lackner (Germany)<\/em>
        \nBiomarkers for cardiovascular risk stratification – S. Blankenberg (Germany<\/em>)<\/li>\n
      • 10:00-10:30 Break<\/li>\n
      • 10:30-12:30 SYMPOSIUM 7<\/strong> | Room 1<\/span>
        \nImplementation of Liquid Biopsy<\/strong>
        \nChairs: M. Neumaier (Germany), V. Haselmann (Germany)<\/em>
        \nLiquid Biopsy\/cell free DNA: talk of the town, but where is the action? \u2013 R. Van Schaik (Netherlands)<\/em>
        \nCancer Epigenetic Biomarkers in Liquid Biopsy \u2013 S. A. Joosse (Germany)<\/em>
        \nThe importance of Integrative molecular analysis in Liquid biopsies – E. Lianidou (Greece)<\/em>
        \nHTA of clinical decision-making of circulating nucleic acids in cancer patients – M. IJzerman (Australia)<\/li>\n
      • 10:30-12:30 SYMPOSIUM 8<\/strong> | Room 5<\/span>
        \nNew approaches for determining reference intervals across all ages<\/strong> – Chairs: Y. Ozarda (Turkey), T. Streichert (Germany)<\/em>
        \nComparison of different approaches for deriving reference intervals – Y. Ozarda (Turkey)<\/em>
        \nAge related RIs: Methods for continuous RIs and possible applications – T. Streichert (Germany)<\/em>
        \nA new computer-intensive approach for the indirect derivation of reference intervals – K. Ichihara (Japan)<\/em>
        \nPediatric Reference Intervals for Trace Elements in the CALIPER cohort of healthy children and adolescents using ICP-MS\/MS and HR-MS Technology – M. K. Bohn (Canada)<\/em>
        \nNUMBER-2: The automation and extension to routine haematology of the Dutch indirect data-mining approach to establish population-specific reference intervals – N. Brouwer (The Netherlands)<\/em><\/li>\n
      • 10:30-12:30 SYMPOSIUM 9<\/strong> | Room 13a<\/span>
        \nNew insights in amyloidosis<\/strong> – Chairs: G. Palladini (Italy), S.O. Sch\u00f6nland (Germany)<\/em>
        \nThe clinical laboratory in the management of systemic amyloidosis: state of the art – G. Palladini (Italy)<\/em>
        \nGenetics of the amyloidogenic plasma cell clone: impact on clinical management – S.O. Sch\u00f6nland (Germany)<\/em>
        \nAssessment of MRD in AL amyloidosis – B. Paiva (Spain)<\/em><\/li>\n
      • 10:30-12:30 SYMPOSIUM 10<\/strong> | Room 13b<\/span>
        \nHow to make EQA fit for purpose?<\/strong> – Chairs: P. Meijer (Netherlands), C. Buchta (Austria)<\/em>
        \nWhat are the fundamental aims of EQA? – C. Buchta (Austria)<\/em>
        \nThe role of EQA in quality assurance of the extra-analytical phase – J. Cadamuro (Austria)<\/em>
        \nPatient results for \u201creal-time\u201d surveillance of pre-analytical and analytical stability – A.E. Solsvik (Norway)<\/em>
        \nDevelopment of an External Quality Assessment (EQA) Programme for SARS-CoV-2 Ab – G. Davies<\/em> (UK)<\/em>
        \nAssessing laboratory performance of hs-c-troponin with EQA data – M. van Schrojenstein Lantman (The Netherlands)<\/em><\/li>\n
      • 10:30-12:30 SYMPOSIUM 11<\/strong> | Room 14a<\/span>
        \nHemostasis<\/strong> – Chairs: B. Lammle (Germany), K. Vanhoorelbeke (Belgium)<\/em>
        \nProcoagulant COAT platelets: Mechanisms and clinical relevance \u2013 L. Alberio (Switzerland)<\/em>
        \nMonitoring of novel therapies of hemophilia in the clinical laboratory – S. Kitchen (UK)
        \n<\/em>Thrombotic thrombocytopenic purpura \u2013 from bench to bedside – K. Vanhoorelbeke (Belgium)
        \n<\/em>Diagnosis and laboratory-guided clinical management of anticoagulant rodenticides poisoning – M. Lenski (France)
        \n<\/em>Multicentre study on the comparison of methods for the measurement of anticoagulant activity in patients treated with DOAC (Direct Oral AntiCoagulants) – M. Vidali (Italy)<\/em><\/li>\n
      • 10:30-12:30 DGKL SYMPOSIUM<\/strong> | Room 14c<\/span>
        \nAutoimmune disorders of coagulation<\/strong> – Chairs: K. Lackner (Germany),<\/em> T. Bakchoul (Germany<\/em>)
        \nImmune thrombocytopenia \u2013 diagnosis and treatment – T. Bakchoul (Germany)<\/em>
        \nPathophysiology and Diagnosis of Antiphospholipid Syndrome – N. M\u00fcller-Calleja (Germany)<\/em>
        \nAcquired hemophilia \u2013 diagnosis and treatment – A. Tiede (Germany)<\/em><\/li>\n
      • 12:30-14:00 POSTER SESSION<\/strong> | Hall C1<\/span><\/li>\n
      • 14:00-16:00 SYMPOSIUM 12<\/strong> | Room 14c<\/span>
        \nNew development in Diagnosis and therapy of dyslipidemia and CVD<\/strong> – Chairs: B. Nordestgaard (Denmark), A. von Eckardstein (Switzerland)<\/em>
        \nAdvances in lipid-lowering therapy through antibody-based and gene-silencing technologies – B. Nordestgaard (Denmark)<\/em>
        \nMeasuring atherogenic lipoproteins that address residual cardiovascular risk beyond LDL-c – M. Langlois (Belgium)<\/em>
        \nThe challenges of measuring apolipoprotein(a) and its relevance for patient management and patient outcome – C. Cobbaert (Netherlands)<\/em>
        \nHDL-Quo vadis? – A. von Eckardstein (Switzerland)<\/em><\/li>\n
      • 15:30-16:30 VIEWPOINT 3<\/strong> | Room 1<\/span>
        \nBiomarkers of alcohol abuse in clinical and forensic use \u2013 strengths and limitations<\/strong> – U. Ceglarek (Germany)<\/em>
        \nCarbohydrate deficient transferrin as marker for alcoholism, its use in comparison with \u2018old\u2019 indirect biomarkers – JPM. Wielders (Netherlands)<\/em>
        \nEthylglucuronide (EtG) \u2013 the one and only (direct) marker of alcohol consumption? – H. Andresen-Streichert (Germany)<\/em><\/li>\n
      • 17:00-18:00 VIEWPOINT 4<\/strong> | Room 1<\/span>
        \nWhich future for HbA1c as biomarker of diabetes monitoring?<\/strong> – Chair: E. Kilpatrick (UK)<\/em>
        \nHbA1c remains the gold standard – G. John (UK)<\/em>
        \nThe future belongs to Time in Range and continuous glucose monitoring indications – D. Leslie (UK)<\/em><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 4″]
        <\/div>

        Wednesday, 13 April<\/h2><\/div><\/div>
          \n
        • 9:00-10:00 PLENARY LECTURE<\/strong> | Room 1<\/span>
          \nChair: M. Neumaier (Germany)<\/em>
          \nIntegrative Diagnostics as the Key Driver for Intelligent Systems in Medicine – S. Sch\u00f6nberg (Germany)<\/em><\/li>\n
        • 10:00-10:30 Break<\/strong><\/li>\n
        • 10:30-12:30 SYMPOSIUM 13<\/strong> | Room 13a<\/span>
          \nPorphyrias \u2013 integration of laboratory medicine and clinical care (A symposium in memorial of the 140 years anniversary of the birth of Hans Fischer)<\/strong> – Chairs: S. Sandberg (Norway), A.K. Aarsand (Norway)<\/em>
          \nHans Fischer and his role in developing the field of porphyria – S. Sandberg (Norway)<\/em>
          \nPractical guidelines on how to diagnose the porphyrias – A.K. Aarsand (Norway)<\/em>
          \nRegulation of the haem biosynthesis – J. Philips (USA)<\/em>
          \nNewer treatment options for porphyria – J.-C. Deybach (France<\/em>)<\/li>\n
        • 10:30-12:30 SYMPOSIUM 14<\/strong> | Room 5<\/span>
          \nAdvances in IQC tools and techniques<\/strong> – Chairs: T. Badrick (Australia), E. Kilpatrick (UK)<\/em>
          \nHow is conventional QC practised now and how can it be improved? – E. Kilpatrick (UK)<\/em>
          \nThe importance of demonstrating commutability of reference materials with IQC – V. Delatour (France)<\/em>
          \nPatient Based Real Time QC \u2013 an introduction – T. Badrick (Australia)<\/em>
          \nPBRTQC \u2013 implementing into routine practice \u2013 validation and simulation – A. Bietenbeck (Germany)<\/em><\/li>\n
        • 10:30-12:30 SYMPOSIUM 15<\/strong> | Room 1<\/span>
          \nHigh-sensitivity troponins and beyond<\/strong> – Chairs: S. Wittfooth (Finland), R. Christenson (USA)<\/em>
          \nAnalytical aspects of high-sensitivity troponin assays: Impact on Clinical Application – Robert Christenson (US)
          \nHigh-sensitivity troponins in clinical use – Paul\u00a0Collinson\u00a0(GB)
          \nTroponin fragments for better specificity? – Saara Wittfooth (FI)<\/li>\n
        • 10:30-12:30 SYMPOSIUM 16<\/strong> | Room 13b<\/span>
          \nHealth platforms of the future and clinical relevance of interoperability<\/strong> – Chair: C. Cobbaert (Netherlands)
          \n<\/em>Defining Interoperability in Healthcare with HL7-FHIR and understanding the potential transformation of pathology \u2013 G. Grieve (Australia)<\/em>
          \nThe value of interoperable communication of pathology requests and results \u2013 K. Sikaris (Australia)<\/em>
          \nIlluminating the Black Box – why and how to do explainable Artificial Intelligence in a medical setting \u2013 A. Tolios (Austria)<\/em><\/li>\n
        • 10:30-12:30 SYMPOSIUM 17<\/strong> | Room 14a<\/span>
          \nNew trends in standardization<\/strong> – Chairs: P. Gillery (France), E. Cavalier (Belgium)<\/em>
          \nStandardization of bone markers – E. Cavalier (Belgium)<\/em>
          \nStandardization in fecal immuno-testing – S. Benton (UK)<\/em>
          \nTraceability chains in Therapeutic drug monitoring: scope, limitations and state of the art – C. Seger (Switzerland)<\/em>
          \nStandardization in glucose monitoring – G. Freckmann (Germany)<\/em><\/li>\n
        • SYMPOSIUM DGKL <\/strong>| Room 14c<\/span>
          \nPersonalised medicine in allergy diagnostics<\/strong> – Chair: Harald Renz (DE)<\/em>
          \nMolecular Diagnosis and Digital Health for Precision Allergology – Paolo Maria Matricardi (IT)<\/em>
          \nAsthma and COPD diagnostics \u2013 lessons learned from multi-centre big data analysis – Harald Renz (DE)<\/em>
          \nThe Janus-faced nature of viral infections in asthma – Chrysanthi\u00a0Skevaki\u00a0(DE)<\/em>
          \nChip-based diagnosis for personalized treatment – Katarzyna\u00a0Niespodziana\u00a0(AT)<\/em><\/li>\n
        • 12:30-14:00 POSTER SESSION<\/strong> | Hall C1<\/span><\/li>\n
        • 14:00-16:00 SYMPOSIUM 18<\/strong> | Room 14c<\/span>
          \nConsequences of IVDR Regulations on Laboratory Medicine<\/strong> – Chairs: C. Cobbaert (Netherlands), P- Monaghan (UK)<\/em>
          \nThe in Vitro Diagnostics Regulation – the perspective of the European Commission – O. Tkachenko (Belgium)
          \n<\/em>Consequences of the IVDR 2017\/746 for the IVD-industry – O. Bisazza (Belgium), I. Slobodeaniuc (Belgium)
          \n<\/em>Consequences of the IVDR 2017\/746 for Notified Bodies – A.F. Stange (Japan)
          \n<\/em>Consequences of the IVDR 2017\/746 for Laboratory Professionals – C. Cobbaert (Netherlands)<\/em><\/li>\n
        • 15:30-16:30 VIEWPOINT 6<\/strong> | Room 1<\/span>
          \nRegulating direct-to-consumer testing 2.0: Protecting the consumer<\/strong> – Chair: B. Gouget (France)<\/em>
          \nIntroduction: What is Direct-to-Consumer (D2C or DTC), how to increase Public Awareness – B. Gouget (FR)<\/em>
          \nOpportunities for decentralized testing in modern healthcare and dangers vs benefits of DTC – J.H. Nichols (USA)<\/em>
          \nAdvocacy for appropriate regulation of biological tests sold directly to consumers – M. Vaubourdolle (France)<\/em><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”DAY 5″]
          <\/div>

          Thursday, 14 April<\/h2><\/div><\/div>
            \n
          • 9:00-10:00 PLENARY LECTURE<\/strong> | Room 1<\/span>
            \nChair: K. Adeli (Canada)<\/em>
            \nTowards next generation diagnostics by X-omics – A. Van Gool (Netherlands)<\/em><\/li>\n
          • 10:00-10:30 Break<\/li>\n
          • 10:30-12:30 SYMPOSIUM 19<\/strong> | Room 14a<\/span>
            \nNew diagnostic approaches in Laboratory Medicine<\/strong> – Chairs: M. Plebani (Italy), S. Bernardini (Italy)<\/em>
            \nExtracellular vesicles in clinical diagnostics – K. Witwer (USA)<\/em>
            \nmiRNA in clinical diagnostics \u2013 can artificial intelligence make the difference? – A. Keller (Germany)<\/em>
            \nWearable biosensors – W. Gao (USA)<\/em>
            \nComparison of reference values for small extracellular particles in a healthy study cohort using Nanoparticle Tracking Analysis (NTA) before and after particle isolation by different isolation methods – B. Betz (Germany)<\/em>
            \nAnalysis of volatile organic compounds (VOCs) in the breath of colorectal cancer (CRC) subjects by Cyranose ‘electronic nose – A. Bonari <\/em>(Italy)<\/em><\/li>\n
          • 10:30-12:30 SYMPOSIUM 20<\/strong> | Room 5<\/span>
            \nAutoimmune Encephalitis<\/strong> – Chairs: A. Vincent (UK)<\/em>
            \nOverview and pathophysiology – A. Vincent (UK)<\/em>
            \nAutoimmune encephalopathies in Neurology – M. Gastaldi (Italy)<\/em>
            \nAutoimmune encephalopathies in Psychiatry – J. Cunningham (Sweden)<\/em><\/li>\n
          • 10:30-12:30 SYMPOSIUM 21<\/strong> | Room 13a<\/span>
            \nUrinalysis: a new look at old tests<\/strong> – Chairs: J. Delanghe (Belgium) – W. Hofmann (Germany)<\/em>
            \nModern urine test strip technology – J. Delanghe (Belgium)<\/em>
            \nAutomated urinalysis – G. Previtali (Italy)<\/em>
            \nThe Revised European Urinalysis Guidelines – T. Kouri (Finland)<\/em>
            \nNew approaches to the study bladder cancers using molecular genetic methods and fluorescence analysis – K. Dubayov\u00e1 (Slovakia)<\/em><\/li>\n
          • 10:30-12:30 SYMPOSIUM 22<\/strong> | Room 13b<\/span>
            \nYoung Scientist Session<\/strong> – Chairs: S. Fares Taie (Argentina), T. Pillay (South Africa)<\/em>
            \nMotivation in the Clinical Laboratory – S. Fares Taie (Argentina)<\/em>
            \nProductivity Tools for Young Scientist Professional \u2013 M. Intan Wibawanti (Indonesia)<\/em>
            \nCareer management for Young Laboratory Scientists – G. Sancesario (Italy)<\/em>
            \nConflict Management amongst Young Laboratory Scientists – A. Rampul (South Africa)<\/em><\/li>\n
          • 10:30-12:30 SYMPOSIUM 23<\/strong> | Room 1<\/span>
            \nHow does Point of Care Testing change the clinical pathways?<\/strong> – Chairs: A. Khan (USA)<\/em>
            \nPoint-of-care Testing: a win-win for all players – A. Khan (USA)<\/em>
            \nIs internal (and external?) quality control necessary for POCT? – E. Jacobs (USA)<\/em>
            \nThe role of POC-testing in the clinical pathway of diagnosing SARS-CoV-2 infection – M.C. Tollanes (Norway)<\/em>
            \nTesting for Anti-Mullerian Hormone: analytical performances and usability of a Point-of-Care assay – D. Gruson (Belgium)<\/em>
            \nHemolysis detection with the H-10 Hemcheck device in whole blood and plasma STAT samples – A. Garcia Osuna (Spain)<\/em><\/li>\n
          • 10:30-12:30 DGKL SYMPOSIUM<\/strong> | Room 14c<\/span>
            \nEmerging infectious diseases \u2013 impact of laboratory diagnosis – Chair:\u00a0M. Klouche (Germany)<\/em>
            \nInfectious disease surveillance \u2013 implications of diagnostic screening strategies \u2013 R.\u00a0D\u00fcrrwald\u00a0(Germany)<\/em>
            \nHigh-throughput LAMP-sequencing for diagnosis of infectious diseases – J.\u00a0Schmid-Burgk\u00a0(Germany)<\/em>
            \nSetting up external quality control measures for SARS-CoV-2 during pandemics – V. Haselmann (Germany)<\/em><\/li>\n
          • 12.30 – 13.30\u00a0\u00a0CLOSING CEREMONY<\/strong> | Room 1<\/span>
            \nClosing Remarks
            \nSpeakers:\u00a0K. Lackner\u00a0(Germany), M. Neumaier (Germany), K.\u00a0Adeli\u00a0(Canada),\u00a0T. Ozben\u00a0(Turkey)
            \nPresentation of 3rd EFLM Strategic Conference
            \nT. Ozben (TR), Chair of the Conference<\/em>
            \nPresentation of WorldLab-Euromedlab Roma 2023
            \nS. Bernardini (Italy), President of the congress<\/em><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

            [vc_row][vc_column][vc_accordion active_tab=”1″ collapsible=”yes” style=”2″][vc_accordion_tab title=”DAY 1″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 2″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 3″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 4″][\/vc_accordion_tab][vc_accordion_tab title=”DAY 5″][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1295"}],"collection":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/comments?post=1295"}],"version-history":[{"count":5,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1295\/revisions"}],"predecessor-version":[{"id":1993,"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/pages\/1295\/revisions\/1993"}],"wp:attachment":[{"href":"https:\/\/www.euromedlab2021munich.org\/index.php\/wp-json\/wp\/v2\/media?parent=1295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}